NCT01522196View on ClinicalTrials.gov

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Sickle Cell DiseaseVaso-occlusive Crisis
Interventions
DRUG

Varespladib

48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.

OTHER

Placebo (Normal Saline)

48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.

Trial Locations (1)

30342

Investigator Site 101, Atlanta

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT01522196 - A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. | Biotech Hunter | Biotech Hunter